Erschienen in:
01.12.2023 | News item
Falsified Ozempic (semaglutide) and Saxenda (liraglutide)
Erschienen in:
Reactions Weekly
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Excerpt
The UK Medicines and Healthcare products regulatory Agency (MHRA) is advising that potentially harmful falsified Ozempic (semaglutide) and Saxenda (liraglutide) products have been found in the UK. Healthcare professionals should be vigilant for symptoms linked to hypoglycaemia in patients who may have obtained falsified Ozempic or Saxenda products containing insulin. They should remind patients using Ozempic or Saxenda to always obtain prescription medicines from a registered pharmacy and not to use products they suspect are falsified as this may lead to serious adverse events. Ozempic and Saxenda from legitimate supply chains are unaffected, said the MHRA. …